Prof Niall Tebbutt
Clinical (Professor)
Department of Surgery
461 Scholarly works
1 Projects
HIGHLIGHTS
2026
Journal article
369P Real-world treatment (tx) outcomes of durvalumab (D)-based regimens in advanced biliary tract cancer (aBTC): LIVER-R interim analysis (IA)
DOI: 10.1016/j.annonc.2026.05.4092026
Journal article
Diagnostic and predictive utility of peritoneal tumor DNA in gastroesophageal cancer: A prospective multicenter study.
DOI: 10.1200/jco.2026.44.16_suppl.41012026
Journal article
Zanidatamab chemotherapy (CT) ± tislelizumab for first-line (1L) HER2-positive (HER2 ) locally advanced or metastatic gastroesophageal adenocarcinoma (mGEA): PD-L1 subgroup analysis from HERIZON-GEA-01.
DOI: 10.1200/jco.2026.44.16_suppl.40102026
Journal article
Real-world treatment patterns and clinical outcomes for patients with deficient mismatch repair (dMMR) metastatic colorectal cancer (mCRC).
DOI: 10.1200/jco.2026.44.16_suppl.e155502026
Journal article
Late-line Systemic Therapy in Metastatic Colorectal Cancer: A Narrative Review and Australian Expert Perspective
DOI: 10.1016/j.clcc.2026.04.0012026
Journal article
A phase 1/2 study of BDC-4182, a Claudin 18.2–targeting next-generation immune-stimulating antibody conjugate (ISAC), in patients with advanced gastric and gastroesophageal cancer.
DOI: 10.1200/jco.2026.44.16_suppl.tps42422017
Research Grant
Mapping Patterns of Care for People With Pancreatic Cancer: How Close Are We to the Optimal Care Pathway Recommendations?
RECENT SCHOLARLY WORKS
2026
Journal article
Characterization and management of gastrointestinal (GI) adverse events (AEs) with zanidatamab chemotherapy (CT) ± tislelizumab in first-line (1L) HER2-positive (HER2 ) locally advanced or metastatic gastroesophageal adenocarcinoma (mGEA): Analysis from HERIZON-GEA-01.
DOI: 10.1200/jco.2026.44.16_suppl.40422026
Journal article
Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer
DOI: 10.1056/NEJMoa25177292026
Journal article
Early-stage multi-cancer detection through a plasma extracellular vesicle protein signature
DOI: 10.1016/j.xcrm.2026.1026942026
Journal article
Abstract CT094: A Phase 1/2 study of BDC-4182, a claudin18.2-targeting next generation immune-stimulating antibody conjugate (ISAC), in patients with advanced gastric and gastroesophageal cancer
DOI: 10.1158/1538-7445.am2026-ct094